<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02880007</url>
  </required_header>
  <id_info>
    <org_study_id>2010-A00235-34</org_study_id>
    <nct_id>NCT02880007</nct_id>
  </id_info>
  <brief_title>Dose Optimization in 3D Pulsed Dose Rate Brachytherapy for Patients With Locally Advanced Cervical Cancer</brief_title>
  <acronym>TRIDICOL</acronym>
  <official_title>A Prospective Open Label Phase II Study to Optimize the Dose in 3D Pulsed Dose Rate Brachytherapy in Patients With Locally Advanced Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de Lorraine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de Lorraine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective phase II trial study aims to optimize the increase in dose to the target
      volume at high risk (85 to 90 Gy over 90% of its volume) and the intermediate target volume
      (60 Gy to 90 % of its volume) in 3D Pulsed Dose Rate Brachytherapy in treating patients with
      locally advanced cervical cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  The causes of treatment failure and death in cervical cancer are still often linked to a
           local cancer progression

        -  The importance of local control for healing, than the cervix situation in the center of
           pelvis between bladder and rectum which are sensitive organs to irradiation justify the
           use of utero-vaginal brachytherapy

        -  This open label, multicenter, phase II study evaluates the benefit of increasing in dose
           to the target volume at high risk and the intermediate target volume in 3D Pulsed Dose
           Rate Brachytherapy in treating patients with locally advanced cervical cancer.

        -  Local control and tolerance are evaluated
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase the local control rate</measure>
    <time_frame>24 months</time_frame>
    <description>Increasing local control in two years (from 71.0% to 86.7%) will be achieved by increasing the dose to the target volume (CTV and CTV-HR-RI) measured dose volume histograms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maintain the cumulative rate grade III and IV complications below 6.5%</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between the doses delivered to the target volume and local control</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between the doses delivered to the critical organs and rate of grade III and IV complications</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Cervical Adenocarcinoma</condition>
  <condition>Stage IB Cervical Cancer</condition>
  <condition>Stage II Cervical Cancer</condition>
  <condition>Stage III Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>ARM A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Optimization in 3D Pulsed Dose Rate Brachytherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External Beam Radiation Therapy</intervention_name>
    <description>45 Gy pelvis / 25 fr</description>
    <arm_group_label>ARM A</arm_group_label>
    <other_name>EBRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>PDR Brachytherapy</intervention_name>
    <description>1 puls/hour ; 12 Gy / day</description>
    <arm_group_label>ARM A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>increase in dose to the target volume at high risk (85 to 90 Gy over 90% of its volume) and the intermediate target volume (60 Gy to 90 % of its volume) in 3D Pulsed Dose Rate Brachytherapy</description>
    <arm_group_label>ARM A</arm_group_label>
    <other_name>CDDP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  primitive cervical cancer

          -  adenocarcinoma histologically advanced

          -  IB2, II and III stage

          -  curative treatment

          -  indication of utero-vaginal brachytherapy with external radiotherapy

          -  non-metastatic tumor and life expectancy &gt; 6 months

          -  patient informed and follow possible

          -  performance status ≤ 2

          -  unplanned surgery

          -  age ≥ 18 years old

          -  ability to provide written informed consent before the start of any study specific
             procedures

        Exclusion Criteria:

          -  primitive endometrial cancer

          -  other diseases

          -  carcinoma in situ and stages ≤ B

          -  distant metastases

          -  history of pelvic irradiation or a first pelvic cancer

          -  contraindication to MRI

          -  history of subtotal or total hysterectomy

          -  pregnant or breast feeding females

          -  inability to support low dose rate continuous brachytherapy or pulsed flow

          -  person in emergencies

          -  person unable to give personally consent

          -  patient participating in another clinical research except in case of local recurrence
             or observational research
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PEIFFERT Didier</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>GILLON Veronique</last_name>
    <phone>0033383598608</phone>
    <email>v.gillon@nancy.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>FERNANDES Laurinda</last_name>
    <phone>0033383598487</phone>
    <email>l.fernandes@nancy.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BARON Marie-Hélène, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>THOMAS Laurence, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>PETIT Adeline, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Georges-François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PEIGNAUX Karine, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>MARTIN Etienne, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>POMMIER Pascal, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>CARRIE Christian, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KERR Christine, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>POP Marius, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DELANNES Martine, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>DUCASSOU Anne, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHRU Tours - Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BARILLOT Isabelle, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PEIFFERT Didier, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>BRUNAUD Claire, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2016</study_first_submitted>
  <study_first_submitted_qc>August 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2016</study_first_posted>
  <last_update_submitted>August 22, 2016</last_update_submitted>
  <last_update_submitted_qc>August 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulsed dose-rate brachytherapy</keyword>
  <keyword>3D dosimetry</keyword>
  <keyword>Prospective Studies</keyword>
  <keyword>Radiotherapy Dosage</keyword>
  <keyword>Uterine Cervical Neoplasms/radiotherapy</keyword>
  <keyword>Brachytherapy/methods</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

